Drugbank Logo

Showing drug card for Ribavirin (DB00811)

Legend: drug field target field enzyme field

for drugs
Version 2.5
Creation Date 2005-06-13 13:24:05
Update Date 2009-06-23 18:07:08
Primary Accession Number DB00811
Secondary Accession Number
  • APRD00081
Name Ribavirin
Drug Type
  • Approved
  • Small Molecule
Description A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]
Synonyms
  1. RBV
  2. Ribavirin Triphosphate
  3. Ribavirina [INN-Spanish]
  4. Ribavirine [INN-French]
  5. Ribavirinum [INN-Latin]
Brand Names
  1. Copegus
  2. RIBAV
  3. RTC
  4. RTCA
  5. RTP
  6. Rebetol
  7. Rebetron
  8. Rebretron
  9. Ribamide
  10. Ribamidil
  11. Ribamidyl
  12. Ribasphere
  13. Ribavirin Capsules
  14. Ribavirin-TP
  15. Tribavirin
  16. Varazid
  17. Vilona
  18. Viramid
  19. Virazid
  20. Virazole
  21. Virazole 5'-triphosphate
Brand Mixtures
  1. Rebetron (Schering-Plough) (Ribavirin + Interferon alpha)
Chemical IUPAC Name 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
Chemical Formula C8H12N4O5
Chemical Structure Structure
CAS Registry Number 36791-04-5
InChI Identifier InChI=1/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1/f/h9H2
InChI Key IWUCXVSUMQZMFG-OHVMRBAQDG
KEGG Drug D00423 Link Image
KEGG Compound Not Available
PubChem Compound 37542 Link Image
PubChem Substance 178906 Link Image
ChEBI ID Not Available
PharmGKB ID PA451241 Link Image
HET ID RTP Link Image
GenBank ID Not Available
Drug ID Number [DIN] Not Available
RxList Link www.rxlist.com/cgi/generic2/ribavirin.htm Link Image
PDRhealth Link Not Available
Wikipedia Link http://en.wikipedia.org/wiki/Ribavirin Link Image
FDA Label
Material Safety Data Sheet (MSDS)
Synthesis Reference Not Available
Average Molecular Weight 244.2047
Monoisotopic Molecular Weight 244.0808
State Solid
Melting Point 174-176 oC
Experimental Water Solubility 142 mg/mL (max, at 25°C) Source: PhysProp
Predicted Water Solubility 3.32e+01 mg/mL Calculated using ALOGPS
Experimental LogP/Hydrophobicity -2.6 Source: PhysProp
Predicted LogP -1.91 Calculated using ALOGPS
Experimental LogS Not Available
Predicted LogS -0.87 Calculated using ALOGPS
Experimental Caco2 Permeability Not Available
pKa/Isoelectric Point Not Available
Mass Spectrum Not Available
MOL File Show Link Image | Download Link Image
SDF File Show Link Image | Download Link Image
PDB File Show Link Image | Download Link Image
2D Structure
3D Structure
Experimental PDB ID 1BX4 Link Image
Experimental PDB File Show
Experimental PDB Structure
Isomeric SMILES NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Canonical SMILES NC(=O)C1=NN(C=N1)C1OC(CO)C(O)C1O
Drug Category
  • Antimetabolites
  • Antiviral Agents
ATC Codes
AHFS Codes
  • 08:18.32
Indication For the treatment of chronic hepatitis C and for respiratory syncytial virus (RSV).
Pharmacology Ribavirin is an anti-viral drug active against a number of DNA and RNA viruses. It is a member of the nucleoside antimetabolite drugs that interfere with duplication of the viral genetic material. The drug inhibits the activity of the enzyme RNA dependent RNA polymerase, due to it's resemblence to building blocks of the RNA molecules. The oral form is used in the treatment of hepatitis C, in combination with interferon drugs. The aerosol form is used to treat respiratory syncytial virus-related diseases in children. The primary serious adverse effect of ribavirin is hemolytic anemia, which may worsen preexisting cardiac disease.
Mechanism of Action Ribavirin is readily phosphorylated intracellularly by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites. Ribavirin triphosphate (RTP) is a potent competitive inhibitor of inosine monophosphate (IMP) dehydrogenase, viral RNA polymerase and messenger RNA (mRNA) guanylyltransferase (viral). Guanylyltranserase inhibition stops the capping of mRNA. These diverse effects result in a marked reduction of intracellular guanosine triphosphate (GTP) pools and inhibition of viral RNA and protein synthesis. Ribavirin is also incorporated into the viral genome causing lethal mutagenesis and a subsequent decrease in specific viral infectivity.
Absorption Rapidly and extensively absorbed following oral administration. However, due to first-pass metabolism, the absolute bioavailability averages 64%.
Toxicity Side effects include "flu-like" symptoms, such as headache, fatigue, myalgia, and fever. The LD50 in mice is 2 g/kg orally and is associated with hypoactivity and gastrointestinal symptoms (estimated human equivalent dose of 0.17 g/kg, based on body surface area conversion).
Protein Binding Not Available
Biotransformation Hepatic. Results of in vitro studies using both human and rat liver microsome preparations indicated little or no cytochrome P450 enzyme-mediated metabolism of ribavirin, with minimal potential for P450 enzyme-based drug interactions. Ribavirin has two pathways of metabolism: (1) a reversible phosphorylation pathway in nucleated cells; and (2) a degradative pathway involving deribosylation and amide hydrolysis to yield a triazole carboxylic acid metabolite.
Half Life 9.5 hours
Dosage Forms
Form Route
Aerosol Respiratory (inhalation)
Patient Information Show Link Image
Contraindications Show Link Image
Interactions Show Link Image
Drug Interactions Not Available
Food Interactions Not Available
Pathways Not Available
General References
  1. Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF: In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res. 2005 Oct;68(1):10-7. [PubMed Link Image]
  2. Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, Morand P, Lunel-Fabiani F, Salmon-Ceron D, Piroth L, Pialoux G, Bentata M, Cacoub P, Perronne C: Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):47-52. [PubMed Link Image]
  3. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS: Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 2006 Oct;13(10):683-9. [PubMed Link Image]
  4. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK: Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972 Aug 25;177(50):705-6. [PubMed Link Image]
  5. Drugs.com Link Image
  6. Wikipedia Link Image
  7. RxList Link Image
Organisms Affected
  • Hepatitis C virus, RSV and other RNA/DNA viruses
Phase 1 Metabolizing Enzymes
  1. Adenosine kinase
Targets
  1. Cytosolic purine 5'-nucleotidase
  2. RNA-directed RNA polymerase catalytic subunit
  3. Ectonucleotide pyrophosphatase/phosphodiesterase family member 1
  4. Large structural protein
  5. Inosine-5'-monophosphate dehydrogenase 1
  6. DNA
Phase 1 Metabolizing Enzyme 1 [top]
Enzyme 1 Name Adenosine kinase
Enzyme 1 Gene Name ADK
Enzyme 1 SwissProt ID P55263 Link Image
Enzyme 1 SNPs SNPJam Report Link Image
Enzyme 1 Protein Sequence >Adenosine kinase 
MAAAEEEPKPKKLKVEAPQALRENILFGMGNPLLDISAVVDKDFLDKYSLKPNDQILAED
KHKELFDELVKKFKVEYHAGGSTQNSIKVAQWMIQQPHKAATFFGCIGIDKFGEILKRKA
AEAHVDAHYYEQNEQPTGTCAACITGDNRSLIANLAAANCYKKEKHLDLEKNWMLVEKAR
VCYIAGFFLTVSPESVLKVAHHASENNRIFTLNLSAPFISQFYKESLMKVMPYVDILFGN
ETEAATFAREQGFETKDIKEIAKKTQALPKMNSKRQRIVIFTQGRDDTIMATESEVTAFA
VLDQDQKEIIDTNGAGDAFVGGFLSQLVSDKPLTECIRAGHYAASIIIRRTGCTFPEKPD
FH
Drug Target 1 [top]
Target 1 ID 289
Target 1 Name Cytosolic purine 5'-nucleotidase
Target 1 Synonyms
  1. 5'-nucleotidase cytosolic II
  2. EC 3.1.3.5
Target 1 Gene Name NT5C2
Target 1 Protein Sequence >Cytosolic purine 5'-nucleotidase 
MSTSWSDRLQNAADMPANMDKHALKKYRREAYHRVFVNRSLAMEKIKCFGFDMDYTLAVY
KSPEYESLGFELTVERLVSIGYPQELLSFAYDSTFPTRGLVFDTLYGNLLKVDAYGNLLV
CAHGFNFIRGPETREQYPNKFIQRDDTERFYILNTLFNLPETYLLACLVDFFTNCPRYTS
CETGFKDGDLFMSYRSMFQDVRDAVDWVHYKGSLKEKTVENLEKYVVKDGKLPLLLSRMK
EVGKVFLATNSDYKYTDKIMTYLFDFPHGPKPGSSHRPWQSYFDLILVDARKPLFFGEGT
VLRQVDTKTGKLKIGTYTGPLQHGIVYSGGSSDTICDLLGAKGKDILYIGDHIFGDILKS
KKRQGWRTFLVIPELAQELHVWTDKSSLFEELQSLDIFLAELYKHLDSSSNERPDISSIQ
RRIKKVTHDMDMCYGMMGSLFRSGSRQTLFASQVMRYADLYAASFINLLYYPFSYLFRAA
HVLMPHESTVEHTHVDINEMESPLATRNRTSVDFKDTDYKRHQLTRSISEIKPPNLFPLA
PQEITHCHDEDDDEEEEEEEE
Target 1 Number of Residues 570
Target 1 Molecular Weight 64970
Target 1 Theoretical pI 6.05
Target 1 GO Classification Not Available
Target 1 General Function Involved in 5'-nucleotidase activity
Target 1 Specific Function May have a critical role in the maintenance of a constant composition of intracellular purine/pyrimidine nucleotides in cooperation with other nucleotidases. Preferentially hydrolyzes inosine 5-prime-monophosphate (IMP) and other purine nucleotides
Target 1 Pathways
Name SMPDB Link KEGG Link
Nicotinate and nicotinamide metabolism SMP00048 Link Image map00760 Link Image
Purine metabolism SMP00050 Link Image map00230 Link Image
Pyrimidine metabolism SMP00046 Link Image map00240 Link Image
Target 1 Reactions
  • a 5'-ribonucleotide + H2O = a ribonucleoside + phosphate
Target 1 Pfam Domain Function
Target 1 Signals
  • None
Target 1 Transmembrane Regions
  • None
Target 1 Essentiality Non-Essential
Target 1 GenBank ID Protein 633071 Link Image
Target 1 UniProtKB/Swiss-Prot ID P49902 Link Image
Target 1 UniProtKB/Swiss-Prot Entry Name 5NTC_HUMAN Link Image
Target 1 PDB ID Not Available
Target 1 Cellular Location
  • Cytoplasm
Target 1 Gene Sequence >1686 bp 
ATGTCGACCTCCTGGAGTGATCGGTTACAGAATGCAGCAGATATGCCTGCTAACATGGAT
AAGCATGCCCTGAAAAAGTATCGTCGAGAAGCCTATCATCGGGTGTTTGTGAACCGAAGT
TTAGCAATGGAAAAGATAAAGTGTTTTGGTTTTGATATGGATTATACCCTTGCTGTGTAC
AAGTCCCCAGAGTATGAGTCCCTTGGTTTTGAGCTTACTGTGGAGAGATTAGTTTCTATT
GGCTATCCCCAGGAGTTGCTCAGCTTTGCTTATGATTCTACATTCCCTACCAGGGGACTT
GTCTTTGACACACTGTATGGAAATCTTTTGAAAGTCGATGCCTATGGAAACCTCTTGGTC
TGTGCACATGGATTTAACTTTATAAGGGGACCAGAAACTAGAGAACAGTATCCAAATAAA
TTTATCCAGCGAGATGATACTGAAAGATTTTACATTCTGAACACACTATTCAACCTACCA
GAGACCTACCTGTTGGCCTGCCTAGTAGATTTTTTTACTAATTGTCCCAGATATACCAGT
TGTGAAACAGGATTTAAAGATGGGGACCTCTTCATGTCCTACCGGAGTATGTTCCAGGAT
GTAAGAGATGCTGTTGACTGGGTTCATTACAAGGGCTCCCTTAAGGAAAAGACAGTTGAA
AATCTTGAGAAGTATGTAGTCAAAGATGGAAAACTGCCTTTGCTTCTGAGCCGGATGAAG
GAAGTAGGGAAAGTATTTCTTGCTACCAACAGTGACTATAAATATACAGATAAAATTATG
ACTTACCTGTTTGACTTCCCACATGGCCCCAAGCCTGGGAGCTCCCATCGACCATGGCAG
TCCTACTTTGACTTGATCTTGGTGGATGCACGGAAACCACTCTTTTTTGGAGAAGGCACA
GTACTGCGTCAGGTGGATACTAAAACTGGCAAGCTGAAAATTGGTACCTACACAGGGCCC
CTACAGCATGGTATCGTCTACTCAGGAGGTTCTTCTGATACGATCTGTGACCTGTTGGGA
GCCAAGGGAAAAGACATTTTGTATATTGGAGATCACATTTTTGGGGACATTTTAAAATCA
AAGAAACGGCAAGGGTGGCGAACTTTTTTGGTGATTCCTGAACTCGCACAGGAGCTACAT
GTCTGGACTGACAAGAGTTCACTTTTCGAAGAACTTCAGAGCTTGGATATTTTCTTGGCT
GAACTCTACAAGCATCTTGACAGCAGTAGCAATGAGCGTCCAGACATCAGTTCCATCCAG
AGACGTATTAAGAAAGTAACTCATGACATGGACATGTGCTATGGGATGATGGGAAGCCTG
TTTCGCAGTGGCTCCCGGCAGACCCTTTTTGCCAGTCAAGTGATGCGTTATGCTGACCTC
TATGCAGCATCTTTCATCAACCTGCTGTATTACCCTTTCAGCTACCTCTTCAGGGCTGCC
CATGTCTTGATGCCTCATGAATCAACGGTGGAGCACACACACGTAGATATCAATGAGATG
GAGTCTCCTCTTGCCACCCGGAACCGCACATCAGTGGATTTCAAAGACACTGACTACAAG
CGGCACCAGCTGACACGGTCAATTAGTGAGATTAAACCTCCCAACCTCTTCCCACTGGCC
CCCCAGGAAATTACACACTGCCATGACGAAGATGATGATGAAGAGGAGGAGGAGGAGGAA
GAATAA
Target 1 GenBank Gene ID
Target 1 GeneCard ID NT5C2 Link Image
Target 1 GenAtlas ID NT5C2 Link Image
Target 1 HGNC ID HGNC:8022 Link Image
Target 1 Chromosome Location 10
Target 1 Locus 10q24.32-q24.33
Target 1 SNPs SNPJam Report Link Image
Target 1 General References
  1. Oka J, Matsumoto A, Hosokawa Y, Inoue S: Molecular cloning of human cytosolic purine 5'-nucleotidase. Biochem Biophys Res Commun. 1994 Nov 30;205(1):917-22. [PubMed Link Image]
Target 1 Drug References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed Link Image]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed Link Image]
Drug Target 2 [top]
Target 2 ID 311
Target 2 Name RNA-directed RNA polymerase catalytic subunit
Target 2 Synonyms
  1. EC 2.7.7.48
  2. PB1
  3. Polymerase basic protein 1
  4. RNA-directed RNA polymerase subunit P1
Target 2 Gene Name PB1
Target 2 Protein Sequence >RNA-directed RNA polymerase catalytic subunit 
MDVNPTLLFLKVPAQNAISTTFPYTGDPPYSHGTGTGYTMDTVNRTHQYSERGRWTKNTE
TGAPQLNPIDGPLPEDNEPSGYAQTDCVLEAMAFLEESHPGIFENSCIETMEVVQQTRVD
KLTQGRQTYDWTLNRNQPAATALANTIEVFRSNGLMANESGRLIDFLKDVMESMDKEEIE
ITTHFQRKRRVRDNVTKKMVTQRTIGKKKQRLNKRSYLIRALTLNTMTKDAERGKLKRRA
IATPGMQIRGFVYFVETLARSICEKLEQSGLPVGGNEKKAKLANVVRKMMTNSQDTEISF
TITGDNTKWNENQNPRMFLAVITYITRNQPEWFRNILSIAPIMFSNKMARLGKGYMFESK
SMKLRTQISAEMLANIDLKYFNDSTRKKIEKIRPLLIDGTASLSPGMMMGMFNMLSTVLG
VSILNLGQKRYTKTTYWWDGLQSSDDFALIVNAPNHAGIQAGVDRFYRTCKLLGINMSKK
KSYINRTGTFEFTSFFYRYGFVANFSMELPSFGVSGINESADMSIGVTVIKNNMINNDLG
PATAQMALQLFIKDYRYTYRCHRGDTQIQTRRSFEIKKLWEQTRSKAGLLVSDGGPNLYN
IRNLHTPEVCLKWELMDEDYQGRLCNPLNPFVSHKEIESVNNAVMMPAHGPAKNMEYDAV
ATTHSWVPKRNRSILNTSQRGILEDEQMYQRCCNLFERFFPSSSYRRPVGISSMVEAMVS
RARIDARIDFESGRIKKEDFTEIMKICSTIEELRRQK
Target 2 Number of Residues 769
Target 2 Molecular Weight 86536
Target 2 Theoretical pI 9.74
Target 2 GO Classification
Function
catalytic activity
transferase activity
transferase activity, transferring phosphorus-containing groups
nucleotidyltransferase activity
RNA-directed RNA polymerase activity
Process
viral life cycle
viral infectious cycle
viral genome replication
physiological process
metabolism
cellular metabolism
nucleobase, nucleoside, nucleotide and nucleic acid metabolism
transcription
Component
Not Available
Target 2 General Function Involved in RNA-directed RNA polymerase activity
Target 2 Specific Function RNA-dependent RNA polymerase which is responsible for replication and transcription of virus segments. Binds the promoter sequence of the encapsidated viral RNA. Displays an endonuclease activity involved in cap-stealing. Cleaves cellular pre-mRNA to generate primers for viral transcription
Target 2 Pathways
Name SMPDB Link KEGG Link
Purine metabolism SMP00050 Link Image map00230 Link Image
Target 2 Reactions
  • nucleoside triphosphate + RNAn = diphosphate + RNAn+1
Target 2 Pfam Domain Function
Target 2 Signals
  • None
Target 2 Transmembrane Regions
  • None
Target 2 Essentiality Essential
Target 2 GenBank ID Protein 324960 Link Image
Target 2 UniProtKB/Swiss-Prot ID P16502 Link Image
Target 2 UniProtKB/Swiss-Prot Entry Name RDRP_IABEI Link Image
Target 2 PDB ID Not Available
Target 2 Cellular Location Not Available
Target 2 Gene Sequence >2274 bp 
ATGGATGTCAATCCGACCTTACTTTTCTTAAAAGTGCCAGCACAAAATGCTATAAGCACA
ACTTTCCCTTATACTGGAGACCCTCCTTACAGCCATGGGACAGGAACAGGGTACACCATG
GATACTGTCAACAGGACACATCAGTACTCAGAAAGGGGAAGATGGACAAAAAACACCGAA
ACTGGAGCACCACAGCTCAACCCAATTGATGGGCCACTACCAGAAGACAATGAACCAAGT
GGTTATGCCCAAACAGATTGTGTATTAGAAGCAATGGCTTTCCTTGAGGAATCCCATCCT
GGTATTTTTGAAAACTCATGTATTGAAACGATGGAGGTTGTTCAGCAAACACGAGTGGAC
AAGCTGACACAAGGCCGACAGACCTATGACTGGACTCTGAATAGAAACCAGCCTGCTGCT
ACAGCATTGGCAAACACAATAGAAGTGTTCAGATCAAATGGCCTCATGGCAAATGAATCC
GGAAGGCTAATAGACTTTCTTAAAGATGTAATGGAGTCAATGGACAAAGAAGAAATAGAG
ATCACAACCCATTTTCAGAGAAAGAGACGGGTGAGGGACAATGTGACTAAGAAAATGGTG
ACACAAAGAACAATAGGCAAAAAGAAACAGAGATTAAACAAAAGGAGTTATCTAATTAGG
GCATTGACCCTGAACACAATGACCAAAGATGCTGAGAGAGGGAAACTAAAACGAAGAGCA
ATTGCAACCCCAGGGATGCAAATAAGGGGGTTTGTATACTTTGTTGAGACACTGGCAAGA
AGTATATGTGAAAAACTTGAACAATCAGGACTGCCAGTTGGAGGAAATGAAAAGAAAGCA
AAGTTGGCAAATGTTGTAAGGAAGATGATGACCAATTCTCAGGACACTGAAATTTCTTTC
ACCATCACTGGAGACAACACCAAATGGAACGAAAATCAAAACCCTAGAATGTTTTTGGCC
GTGATCACATATATAACCAGAAATCAGCCCGAATGGTTCAGAAATATTCTAAGTATTGCT
CCAATAATGTTCTCAAACAAAATGGCGAGACTAGGTAAGGGTTACATGTTTGAGAGCAAG
AGTATGAAACTTAGAACTCAAATATCTGCAGAAATGCTAGCAAACATCGATTTGAAGTAT
TTCAATGATTCAACAAGAAAGAAAATTGAAAAAATCCGGCCGCTCTTAATAGATGGGACT
GCATCACTGAGCCCTGGAATGATGATGGGCATGTTCAATATGTTAAGCACTGTATTGGGC
GTTTCCATCCTGAATCTTGGACAAAAGAGATACACAAAGACTACTTACTGGTGGGATGGT
CTTCAATCATCTGATGATTTTGCTCTGATTGTGAATGCACCCAATCATGCAGGAATTCAG
GCTGGAGTTGACAGGTTTTATCGAACTTGTAAGCTGCTCGGAATCAATATGAGTAAGAAA
AAGTCTTACATAAACAGAACAGGTACATTTGAATTCACTAGCTTTTTCTATCGTTATGGG
TTTGTTGCCAATTTCAGCATGGAGCTTCCCAGTTTTGGGGTGTCTGGGATCAACGAGTCT
GCAGATATGAGTATTGGGGTCACTGTCATCAAAAACAATATGATAAACAATGATCTTGGT
CCAGCAACCGCTCAAATGGCCCTTCAGTTATTCATCAAAGATTACAGGTACACGTATCGG
TGCCACAGAGGTGACACACAAATACAAACCCGAAGATCATTTGAAATAAAGAAACTGTGG
GAGCAAACCCGTTCCAAAGCTGGGCTGCTGGTCTCCGATGGAGGTCCTAACTTATATAAC
ATTAGAAATCTCCACACCCCTGAAGTCTGTTTGAAATGGGAATTGATGGATGAGGATTAC
CAGGGGCGTTTATGCAACCCATTGAACCCATTTGTCAGTCATAAAGAGATTGAATCAGTG
AACAATGCAGTGATGATGCCGGCACATGGTCCAGCCAAAAACATGGAGTATGATGCTGTA
GCAACAACACACTCCTGGGTCCCCAAAAGAAATCGATCCATCTTGAATACTAGTCAAAGG
GGAATACTTGAAGATGAACAAATGTATCAAAGGTGCTGCAATTTATTTGAAAGGTTCTTC
CCCAGCAGTTCATACAGAAGGCCAGTCGGAATATCCAGTATGGTGGAGGCTATGGTTTCC
AGAGCCCGAATTGATGCACGGATTGATTTCGAATCTGGAAGGATAAAGAAAGAGGATTTC
ACTGAGATCATGAAGATCTGTTCCACCATTGAAGAACTCAGACGGCAAAAATAG
Target 2 GenBank Gene ID
Target 2 GeneCard ID Not Available
Target 2 GenAtlas ID Not Available
Target 2 HGNC ID Not Available
Target 2 Chromosome Location Not Available
Target 2 Locus Not Available
Target 2 SNPs SNPJam Report Link Image
Target 2 General References
  1. Kawaoka Y, Krauss S, Webster RG: Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol. 1989 Nov;63(11):4603-8. [PubMed Link Image]
Target 2 Drug References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed Link Image]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed Link Image]
Drug Target 3 [top]
Target 3 ID 508
Target 3 Name Ectonucleotide pyrophosphatase/phosphodiesterase family member 1
Target 3 Synonyms
  1. E- NPP 1
  2. EC 3.1.4.1
  3. EC 3.6.1.9
  4. Nucleotide pyrophosphatase
  5. Phosphodiesterase I/nucleotide pyrophosphatase 1
  6. Plasma-cell membrane glycoprotein PC-1
Target 3 Gene Name ENPP1
Target 3 Protein Sequence >Ectonucleotide pyrophosphatase/phosphodiesterase 1 
MERDGCAGGGSRGGEGGRAPREGPAGNGRDRGRSHAAEAPGDPQAAASLLAPMDVGEEPL
EKAARARTAKDPNTYKVLSLVLSVCVLTTILGCIFGLKPSCAKEVKSCKGRCFERTFGNC
RCDAACVELGNCCLDYQETCIEPEHIWTCNKFRCGEKRLTRSLCACSDDCKDKGDCCINY
SSVCQGEKSWVEEPCESINEPQCPAGFETPPTLLFSLDGFRAEYLHTWGGLLPVISKLKK
CGTYTKNMRPVYPTKTFPNHYSIVTGLYPESHGIIDNKMYDPKMNASFSLKSKEKFNPEW
YKGEPIWVTAKYQGLKSGTFFWPGSDVEINGIFPDIYKMYNGSVPFEERILAVLQWLQLP
KDERPHFYTLYLEEPDSSGHSYGPVSSEVIKALQRVDGMVGMLMDGLKELNLHRCLNLIL
ISDHGMEQGSCKKYIYLNKYLGDVKNIKVIYGPAARLRPSDVPDKYYSFNYEGIARNLSC
REPNQHFKPYLKHFLPKRLHFAKSDRIEPLTFYLDPQWQLALNPSERKYCGSGFHGSDNV
FSNMQALFVGYGPGFKHGIEADTFENIEVYNLMCDLLNLTPAPNNGTHGSLNHLLKNPVY
TPKHPKEVHPLVQCPFTRNPRDNLGCSCNPSILPIEDFQTQFNLTVAEEKIIKHETLPYG
RPRVLQKENTICLLSQHQFMSGYSQDILMPLWTSYTVDRNDSFSTEDFSNCLYQDFRIPL
SPVHKCSFYKNNTKVSYGFLSPPQLNKNSSGIYSEALLTTNIVPMYQSFQVIWRYFHDTL
LRKYAEERNGVNVVSGPVFDFDYDGRCDSLENLRQKRRVIRNQEILIPTHFFIVLTSCKD
TSQTPLHCENLDTLAFILPHRTDNSESCVHGKHDSSWVEELLMLHRARITDVEHITGLSF
YQQRKEPVSDILKLKTHLPTFSQED
Target 3 Number of Residues 940
Target 3 Molecular Weight 104925
Target 3 Theoretical pI 7.14
Target 3 GO Classification
Function
catalytic activity
hydrolase activity
hydrolase activity, acting on ester bonds
nuclease activity
endonuclease activity
binding
nucleic acid binding
Process
physiological process
metabolism
cellular metabolism
nucleobase, nucleoside, nucleotide and nucleic acid metabolism
nucleotide metabolism
Component
Not Available
Target 3 General Function Involved in nucleic acid binding
Target 3 Specific Function Has a broad specificity and cleaves a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds of nucleotides and nucleotide sugars. Can hydrolyze nucleoside 5' triphosphates such as ATP, GTP, CTP, TTP and UTP to their corresponding monophosphates with release of pyrophosphate. Can hydrolyze diadenosine polyphosphates and 3',5'-cAMP to AMP. It may play a role in the regulation of pyrophosphate production, the regulation of the availability of nucleotide sugars in the endoplasmic reticulum and Golgi, and the regulation of purinergic signaling
Target 3 Pathways
Name SMPDB Link KEGG Link
Nicotinate and nicotinamide metabolism SMP00048 Link Image map00760 Link Image
Pantothenate and CoA biosynthesis SMP00027 Link Image map00770 Link Image
Purine metabolism SMP00050 Link Image map00230 Link Image
Riboflavin metabolism SMP00070 Link Image map00740 Link Image
Starch and sucrose metabolism SMP00058 Link Image map00500 Link Image
Target 3 Reactions
  • Hydrolytically removes 5'-nucleotides successively from the 3'-hydroxy termini of 3'-hydroxy-terminated oligonucleotides
Target 3 Pfam Domain Function
Target 3 Signals
  • None
Target 3 Transmembrane Regions
  • 77-97
Target 3 Essentiality Non-Essential
Target 3 GenBank ID Protein 189650 Link Image
Target 3 UniProtKB/Swiss-Prot ID P22413 Link Image
Target 3 UniProtKB/Swiss-Prot Entry Name ENPP1_HUMAN Link Image
Target 3 PDB ID Not Available
Target 3 Cellular Location
  • Membrane
  • single-pass type II membrane protein
Target 3 Gene Sequence >2778 bp 
ATGGAGCGCGACGGCTGCGCGGGGGGCGGGAGCCGCGGCGGCGAGGGCGGGCGCGCTCCC
CGGGAGGGCCCGGCGGGGAACGGCCGCGATCGGGGCCGCAGCCACGCTGCCGAGGCGCCC
GGGGACCCGCAGGCGGCCGCGTCCTTGCTGGCCCCTATGGACGTGGGGGAGGAGCCGCTG
GAGAAGGCGGCGCGCGCCCGCACTGCCAAGGACCCCAACACCTATAAAGTACTCTCGCTG
GTATTGTCAGTATGTGTGTTAACAACAATACTTGGTTGTATATTTGGGTTGAAACCAAGC
TGTGCCAAAGAAGTTAAAAGTTGCAAAGGTCGCTGTTTCGAGAGAACATTTGGGAACTGT
CGCTGTGATGCTGCCTGTGTTGAGCTTGGAAACTGCTGTTTAGATTACCAGGAGACGTGC
ATAGAACCAGAACATATATGGACTTGCAACAAATTCAGGTGTGGTGAGAAAAGGTTGACC
AGAAGCCTCTGTGCCTGTTCAGATGACTGCAAGGACAAGGGCGACTGCTGCATCAACTAC
AGTTCTGTGTGTCAAGGTGAGAAAAGTTGGGTAGAAGAACCATGTGAGAGCATTAATGAG
CCACAGTGCCCAGCAGGGTTTGAAACGCCTCCTACCCTCTTATTTTCTTTGGATGGATTC
AGGGCAGAATATTTACACACTTGGGGTGGACTTCTTCCTGTTATTAGCAAACTAAAAAAA
TGTGGAACATATACTAAAAACATGAGACCGGTATATCCAACAAAAACTTTCCCCAATCAC
TACAGCATTGTCACCGGATTGTATCCAGAATCTCATGGCATAATCGACAATAAAATGTAT
GATCCCAAAATGAATGCTTCCTTTTCACTTAAAAGTAAAGAGAAATTTAATCCTGAGTGG
TACAAAGGAGAACCAATTTGGGTCACAGCTAAGTATCAAGGCCTCAAGTCTGGCACATTT
TTCTGGCCAGGATCAGATGTGGAAATTAACGGAATTTTCCCAGACATCTATAAAATGTAT
AATGGTTCAGTACCATTTGAAGAAAGGATTTTAGCTGTTCTTCAGTGGCTACAGCTTCCT
AAAGATGAAAGACCACACTTTTACACTCTGTATTTAGAAGAACCAGATTCTTCAGGTCAT
TCATATGGACCAGTCAGCAGTGAAGTCATCAAAGCCTTGCAGAGGGTTGATGGTATGGTT
GGTATGCTGATGGATGGTCTGAAAGAGCTGAACTTGCACAGATGCCTGAACCTCATCCTT
ATTTCAGATCATGGCATGGAACAAGGCAGTTGTAAGAAATACATATATCTGAATAAATAT
TTGGGGGATGTTAAAAATATTAAAGTTATCTATGGACCTGCAGCTCGATTGAGACCCTCT
GATGTCCCAGATAAATACTATTCATTTAACTATGAAGGCATTGCCCGAAATCTTTCTTGC
CGGGAACCAAACCAGCACTTCAAACCTTACCTGAAACATTTCTTACCTAAGCGTTTGCAC
TTTGCTAAGAGTGATAGAATTGAGCCCTTGACATTCTATTTGGACCCTCAGTGGCAACTT
GCATTGAATCCCTCAGAAAGGAAATATTGTGGAAGTGGATTTCATGGCTCTGACAATGTA
TTTTCAAATATGCAAGCCCTCTTTGTTGGCTATGGACCTGGATTCAAGCATGGCATTGAG
GCTGACACCTTTGAAAACATTGAAGTCTATAACTTAATGTGTGATTTACTGAATTTGACA
CCGGCTCCTAATAACGGAACTCATGGAAGTCTTAACCACCTTCTAAAGAATCCTGTTTAT
ACGCCAAAGCATCCCAAAGAAGTGCACCCCCTGGTACAGTGCCCCTTCACAAGAAACCCC
AGAGATAACCTTGGCTGCTCATGTAACCCTTCGATTTTGCCGATTGAGGATTTTCAAACA
CAGTTCAATCTGACTGTGGCAGAAGAGAAGATTATTAAGCATGAAACTTTACCCTATGGA
AGACCTAGAGTTCTCCAGAAGGAAAACACCATCTGTCTTCTTTCCCAGCACCAGTTTATG
AGTGGATACAGCCAAGACATCTTAATGCCCCTTTGGACATCCTATACCGTGGACAGAAAT
GACAGTTTCTCTACGGAAGACTTCTCCAACTGTCTGTACCAGGACTTTAGAATTCCTCTT
AGTCCTGTCCATAAATGTTCATTTTATAAAAATAACACCAAAGTGAGTTACGGGTTCCTC
TCCCCACCACAACTAAATAAAAATTCAAGTGGAATATATTCTGAAGCTTTGCTTACTACA
AATATAGTGCCAATGTACCAGAGTTTTCAAGTTATATGGCGCTACTTTCATGACACCCTA
CTGCGAAAGTATGCTGAAGAAAGAAATGGTGTCAATGTCGTCAGTGGTCCTGTGTTTGAC
TTTGATTATGATGGACGTTGTGATTCCTTAGAGAATCTGAGGCAAAAAAGAAGAGTCATC
CGTAACCAAGAAATTTTGATTCCAACTCACTTCTTTATTGTGCTAACAAGCTGTAAAGAT
ACATCTCAGACGCCTTTGCACTGTGAAAACCTAGACACCTTAGCTTTCATTTTGCCTCAC
AGGACTGATAACAGCGAGAGCTGTGTGCATGGGAAGCATGACTCCTCATGGGTTGAAGAA
TTGTTAATGTTACACAGAGCACGGATCACAGATGTTGAGCACATCACTGGACTCAGCTTC
TATCAACAAAGAAAAGAGCCAGTTTCAGACATTTTAAAGTTGAAAACACATTTGCCAACC
TTTAGCCAAGAAGACTGA
Target 3 GenBank Gene ID
Target 3 GeneCard ID ENPP1 Link Image
Target 3 GenAtlas ID ENPP1 Link Image
Target 3 HGNC ID HGNC:3356 Link Image
Target 3 Chromosome Location 6
Target 3 Locus 6q22-q23
Target 3 SNPs SNPJam Report Link Image
Target 3 General References
  1. Nakamura I, Ikegawa S, Okawa A, Okuda S, Koshizuka Y, Kawaguchi H, Nakamura K, Koyama T, Goto S, Toguchida J, Matsushita M, Ochi T, Takaoka K, Nakamura Y: Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL). Hum Genet. 1999 Jun;104(6):492-7. [PubMed Link Image]
  2. Pizzuti A, Frittitta L, Argiolas A, Baratta R, Goldfine ID, Bozzali M, Ercolino T, Scarlato G, Iacoviello L, Vigneri R, Tassi V, Trischitta V: A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes. 1999 Sep;48(9):1881-4. [PubMed Link Image]
  3. Funakoshi I, Kato H, Horie K, Yano T, Hori Y, Kobayashi H, Inoue T, Suzuki H, Fukui S, Tsukahara M, et al.: Molecular cloning of cDNAs for human fibroblast nucleotide pyrophosphatase. Arch Biochem Biophys. 1992 May 15;295(1):180-7. [PubMed Link Image]
  4. Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11. [PubMed Link Image]
  5. Buckley MF, Loveland KA, McKinstry WJ, Garson OM, Goding JW: Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location. J Biol Chem. 1990 Oct 15;265(29):17506-11. [PubMed Link Image]
  6. Belli SI, Mercuri FA, Sali A, Goding JW: Autophosphorylation of PC-1 (alkaline phosphodiesterase I/nucleotide pyrophosphatase) and analysis of the active site. Eur J Biochem. 1995 Mar 15;228(3):669-76. [PubMed Link Image]
  7. Belli SI, Goding JW: Biochemical characterization of human PC-1, an enzyme possessing alkaline phosphodiesterase I and nucleotide pyrophosphatase activities. Eur J Biochem. 1994 Dec 1;226(2):433-43. [PubMed Link Image]
Target 3 Drug References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed Link Image]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed Link Image]
Drug Target 4 [top]
Target 4 ID 752
Target 4 Name Large structural protein
Target 4 Synonyms
  1. Protein L
  2. Replicase
  3. Transcriptase
Target 4 Gene Name L
Target 4 Protein Sequence >Large structural protein 
MAASSEILLPEVHLNSPIVKHKLIYYLLLGHFPHDLDISEISPLHNNDWDQIAREESNLA
ERLGVAKSELIKRVPAFRATRWRSHAAVLIWPSCIPFLVKFLPHSKLQPVEQWYKLINAS
CNTISDSIDRCMENISIKLTGKNNLFSRSRGTAGAGKNSKITLNDIQSIWESNKWQPNVS
LWLTIKYQMRQLIMHQSSRQPTDLVHIVDTRSGLIVITPELVICFDRLNSVLMYFTFEMT
LMVSDMFEGRMNVTALCTISHYLSPLGPRIDRLFSIVDELAQLLGDTVYKVIASLESLVY
GCLQLKDPVVELAGSFHSFITQEIIDILIGSKALDKDESITVTTQLLDIFSNLSPDLIAE
MLCLMRLWGHPTLTAAQVGKVRESMCAGKLLDFPTIMKTLAFFHTILINGYRRKKNGMWP
PLILPKNASKSLIEFQHDNAEISYEYTLKHWKEISLIEFRKCFDFDPGEELSIFMKDKAI
SAPRSDWMSVFRRSLIKQRHQRHHIPMPNPFNRRLLLNFLEDDSFDPVAELRYVTGGEYL
QDDTFCASYSLKEKEIKPDGRIFAKLTNRMRSCQVIAEAILANHAGTLMKENGVVLNQLS
LTKSLLTMSQIGIISEKAKRYTRDNISSQGFHTIKTDSKNKRKSKTASSYLTDPDDTFEL
SACFITTDLAKYCLQWRYQTIIHFARTLNRMYGVPHLFEWIHLRLIRSTLYVGDPFNPPA
ATDAFDLDKVLNGDIFIVSKGGIEGLCQKMWTMISISVIILSSAESKTRVMSMVQGDNQA
IAVTTRVPRSLPSIQKKELAYAASKLFFERLRANNYGLGHQLKAQETIISSTFFIYSKRV
FYQGRILTQALKNASKLCLTADVLGECTQASCSNSATTIMRLTENGVEKDTCYKLNIYQS
IRQLTYDLIFPQYSIPGETISEIFLQHPRLISRIVLLPSQLGGLNYLACSRLFNRNIGDP
LGTAVADLKRLIKCGALESWILYNLLARKPGKGSWATLAADPYSLNQEYLYPPTTILKRH
TQNTLMEICRNPMLKGVFTDNAKEEENLLAKFLLDRDIVLPRVAHIIIDQSSIGRKKQIQ
GFFDTTRTIMRRSFEIKPLSTKKTLSVIEYNTNYLSYNYPVILNPLPIPGYLNYITDQTC
SIDISRSLRKLSWSSLLNGRTLEGLETPDPIEVVNGFLIVGTGDCDFCMQGDDKFTWFFL
PMGIIIDGNPETNPPIRVPYIGSRTEERRVASMAYIKGATHSLKAALRGAGVYIWAFGDT
VVNWNDALDIANTRVKISLEQLQTLTPLPTSANITHRLDDGATTLKFTPASSYAFSSYTH
ISNDQQYLEIDQRVVDSNIIYQQLMITGLGIIETYHNPPIRTSTQEITLHLHTSSSCCVR
SVDGCLICESNGEVPQITVPYTNTFVYDPDPLADYEIAHLDYLSYQAKIGSTDYYSLTDK
IDLLAHLTAKQMINSIIGLDETVSIVNDAVILSDYTNNWISECSYTKIDLVFKLMAWNFL
LELAFQMYYLRISSWTNIFDYTYMTLRRIPGTALNNIAATISHPKLLRRAMNLDIITPIH
APYLASLDYVKLSIDAIQWGVKQVLADLSNGIDLEILILSEDSMEISDRAMNLIARKLTL
LALVKGENYTFPKIKGMPPEEKCLVLTEYLAMCYQNTHHLDPDLQKYLYNLTNPKLTAFP
SNNFYLTRKILNQIRESDEGQYIITSYYESFEQLETDIILHSTLTAPYDNSENSNKVRFI
PFDIFPHPESLEKYPLPVDHDSQSAISTLIPGPPSHHVLRPLGVSSTAWYKGISYCRYLE
TQKIQTGDHLYLAEGSGASMSLLELLFPGDTVYYNSLFSSGENPPQRNYAPLPTQFVQSV
PYKLWQADLADDSNLIKDFVPLWNGNGAVTDLSTKDAVAFIIHKVGAEKASLVHIDLEST
ANINQQTLSRSQIHSLIIATTVLKRGGILIYKTSWLPFSRFSQLAGLLWCFFDRIHLIRS
SYSDPHSHEVYLVCRLAADFRTIGFSAALVTATTLHNDGFTTIHPDVVCSYWQHHLENVG
RVGKVIDEILDGLATNFFAGDNGLILRCGGTPSSRKWLEIDQLASFDLVQDALVTLITIH
LKEIIEVQSSHTEDYTSLLFTPYNIGAAGKVRTIIKLILERSLMYTVRNWLVLPSSIRDS
VRQDLELGSFRLMSILSEQTFLKKTPTKKYLLDQLTRTYISTFFNSHSVLPLHRPYQKQI
WKALGSVIYCSETVDIPLIKDIQIEDINDFEDIERGIDGEEL
Target 4 Number of Residues 2299
Target 4 Molecular Weight 256386
Target 4 Theoretical pI 6.97
Target 4 GO Classification
Function
catalytic activity
transferase activity
transferase activity, transferring phosphorus-containing groups
nucleotidyltransferase activity
RNA-directed RNA polymerase activity
binding
nucleic acid binding
RNA binding
Process
physiological process
metabolism
cellular metabolism
nucleobase, nucleoside, nucleotide and nucleic acid metabolism
transcription
Component
Not Available
Target 4 General Function Involved in RNA binding
Target 4 Specific Function Displays RNA-directed RNA polymerase, mRNA guanylyl transferase, mRNA (guanine-7-N-)-methyltransferase and poly(A) synthetase activities. The viral mRNA guanylyl transferase displays a different biochemical reaction than the cellular enzyme. The template is composed of the viral RNA tightly encapsidated by the nucleoprotein (N). Functions either as transcriptase or as replicase. The transcriptase synthesizes subsequently the subgenomic RNAs, assuring their capping and polyadenylation by a stuttering mechanism. The transcriptase stutters on a specific sequence, resulting on a cotranscriptional editing of the phosphoprotein (P) mRNA. The replicase mode is dependent on intracellular N protein concentration. In this mode, the polymerase replicates the whole viral genome without recognizing the transcriptional signals
Target 4 Pathways
Name SMPDB Link KEGG Link
Purine metabolism SMP00050 Link Image map00230 Link Image
Target 4 Reactions
  • S-adenosyl-L-methionine + G(5')pppR-RNA = S-adenosyl-L-homocysteine + m7G(5')pppR-RNA (mRNA containing an N7-methylguanine cap)
Target 4 Pfam Domain Function
Target 4 Signals
  • None
Target 4 Transmembrane Regions
  • None
Target 4 Essentiality Non-Essential
Target 4 GenBank ID Protein 61991 Link Image
Target 4 UniProtKB/Swiss-Prot ID P26676 Link Image
Target 4 UniProtKB/Swiss-Prot Entry Name L_PI2HT Link Image
Target 4 PDB ID Not Available
Target 4 Cellular Location
  • Cytoplasm
Target 4 Gene Sequence >6789 bp 
ATGGCGGCCTCTTCTGAGATACTCCTTCCTGAAGTCCACTTGAACTCACCAATAGTCAAA
CACAAACTCATATACTACTTATTACTAGGGCACTTCCCGCATGATCTTGACATTTCTGAA
ATAAGCCCCCTTCACAATAATGATTGGGATCAAATTGCCAGAGAAGAATCCAATCTTGCT
GAACGACTTGGAGTAGCTAAATCTGAATTAATTAAACGTGTGCCCGCATTTAGAGCAACT
AGATGGCGTAGTCATGCAGCCGTCCTTATATGGCCTTCTTGTATACCATTTCTTGTTAAA
TTCCTACCTCATTCTAAGCTTCAACCAGTAGAACAATGGTACAAGTTGATCAATGCTTCA
TGTAATACTATATCTGACTCAATTGATAGATGTATGGAGAATATTTCTATTAAGCTTACT
GGGAAAAACAATCTATTCTCTCGATCCAGAGGAACTGCAGGTGCAGGTAAAAACAGTAAA
ATCACCCTCAATGATATCCAATCTATTTGGGAATCAAACAAGTGGCAACCTAATGTATCT
TTATGGCTTACAATTAAATACCAAATGCGACAACTTATAATGCATCAAAGTTCTCGTCAG
CCGACTGATTTAGTTCACATTGTTGACACACGATCTGGTCTAATAGTTATCACCCCTGAA
CTTGTTATTTGTTTTGATCGGTTAAATAGTGTTTTAATGTATTTTACATTTGAGATGACT
TTAATGGTAAGTGACATGTTTGAGGGAAGGATGAATGTCACCGCTCTCTGCACTATTAGT
CATTACTTATCTCCACTAGGGCCAAGGATAGATAGATTGTTTTCCATTGTAGATGAATTA
GCACAACTATTAGGTGACACTGTATATAAAGTTATTGCATCTCTTGAATCTTTAGTATAT
GGGTGTCTACAACTTAAAGATCCAGTAGTGGAATTAGCAGGGTCATTTCATTCCTTTATT
ACACAAGAGATTATAGATATCCTAATTGGTTCAAAAGCCCTTGATAAGGATGAATCAATA
ACTGTTACTACACAATTGTTAGATATATTTTCCAACCTTTCTCCAGATTTAATTGCTGAG
ATGTTGTGTCTCATGAGACTTTGGGGTCATCCCACTCTTACTGCTGCGCAAGTGGGTAAA
GTGAGAGAATCTATGTGTGCAGGTAAGTTACTTGATTTCCCTACAATAATGAAAACTCTT
GCTTTTTTCCACACAATTTTAATTAATGGTTACCGTAGAAAGAAAAATGGAATGTGGCCT
CCACTTATACTTCCTAAAAATGCATCAAAAAGCTTAATAGAATTTCAACATGATAATGCT
GAAATATCTTACGAATATACACTCAAGCATTGGAAAGAGATATCTCTCATAGAATTTAGA
AAGTGCTTTGACTTTGATCCTGGTGAGGAGCTAAGCATTTTTATGAAAGACAAGGCAATA
AGTGCTCCAAGAAGTGATTGGATGAGTGTATTTCGTAGAAGTCTAATAAAACAACGACAT
CAGAGACATCATATTCCTATGCCCAATCCATTTAATAGACGTCTATTACTCAATTTCTTA
GAAGATGACAGTTTTGATCCAGTTGCCGAGCTTCGATATGTTACCGGTGGTGAATATCTC
CAAGATGACACATTTTGTGCATCTTACTCATTAAAAGAGAAAGAAATAAAACCAGATGGA
AGGATATTTGCTAAGCTTACTAATAGAATGCGGTCCTGTCAAGTAATTGCGGAAGCAATT
CTCGCAAATCATGCAGGTACTCTAATGAAGGAAAACGGAGTTGTCTTGAATCAATTATCA
CTGACTAAATCATTGCTTACTATGAGTCAAATTGGCATAATATCAGAAAAGGCGAAGAGA
TATACGCGAGATAACATCTCATCCCAAGGTTTCCATACAATCAAGACTGATTCTAAAAAT
AAGAGGAAAAGCAAAACTGCATCATCATACCTCACAGATCCTGATGATACATTTGAACTT
AGTGCATGTTTTATAACTACTGATCTTGCTAAATACTGTCTTCAATGGAGATATCAGACC
ATAATCCATTTTGCTCGAACATTAAACAGAATGTATGGAGTTCCACATTTATTTGAATGG
ATTCATCTTCGTTTAATTAGATCTACATTATATGTTGGTGATCCATTCAATCCTCCTGCC
GCAACTGATGCTTTCGATCTAGATAAAGTATTAAATGGTGATATCTTTATAGTCTCCAAG
GGAGGTATTGAAGGCCTATGTCAGAAAATGTGGACAATGATCTCTATTTCTGTGATCATC
CTCTCTTCAGCCGAATCCAAAACAAGAGTAATGAGCATGGTTCAAGGAGATAATCAGGCG
ATTGCAGTTACAACAAGAGTTCCTAGATCATTACCTAGTATTCAGAAAAAGGAGTTAGCC
TATGCAGCAAGCAAGTTATTTTTTGAAAGACTTAGGGCAAATAATTATGGGTTGGGTCAT
CAGCTAAAGGCTCAAGAAACTATAATAAGTTCCACGTTCTTCATATATAGTAAACGGGTA
TTTTATCAAGGACGTATACTAACACAGGCACTCAAAAATGCTAGCAAGTTATGTCTTACT
GCAGATGTATTAGGTGAATGTACTCAAGCTTCCTGTTCAAATTCTGCTACTACCATCATG
AGATTAACAGAAAATGGGGTTGAGAAAGATACATGTTATAAGCTTAATATTTATCAGTCC
ATTCGTCAACTCACATATGATCTAATATTTCCCCAATACTCCATACCAGGTGAAACTATA
AGTGAGATTTTCCTACAGCATCCAAGACTAATCTCACGTATTGTTCTGCTCCCTTCACAG
CTAGGTGGTCTTAATTACCTCGCATGTAGCAGATTATTTAACCGCAATATCGGAGATCCT
CTTGGTACAGCTGTGGCAGATCTCAAGAGGTTAATTAAATGTGGTGCTCTTGAATCATGG
ATACTGTATAATTTACTAGCAAGAAAACCAGGGAAAGGTTCATGGGCAACTTTAGCAGCC
GATCCATACTCATTGAATCAAGAATATCTTTATCCTCCTACTACTATACTTAAAAGACAT
ACTCAAAATACTTTAATGGAGATATGTCGGAATCCTATGTTAAAGGGAGTTTTTACAGAT
AATGCAAAAGAGGAGGAAAATCTCCTTGCAAAATTTCTTCTTGATCGTGATATAGTATTG
CCAAGAGTTGCACACATTATAATAGATCAATCTAGCATCGGAAGGAAGAAACAGATACAA
GGATTTTTTGACACCACAAGGACCATAATGAGACGATCATTTGAAATCAAACCACTCTCA
ACTAAGAAGACTCTTTCAGTCATAGAATATAATACTAATTACTTATCTTATAACTACCCT
GTCATACTTAATCCTTTACCTATTCCTGGATATTTAAATTATATTACTGACCAAACTTGC
AGTATTGATATATCTAGAAGTTTAAGAAAATTATCATGGTCTTCTTTATTGAATGGAAGA
ACTTTAGAAGGATTAGAAACTCCAGATCCAATTGAAGTTGTCAATGGTTTCTTGATTGTA
GGTACAGGAGATTGTGATTTTTGTATGCAGGGTGACGACAAATTTACTTGGTTCTTTTTA
CCTATGGGGATAATTATTGATGGAAATCCTGAAACTAATCCACCCATCAGAGTTCCATAC
ATTGGGTCTAGAACAGAGGAAAGAAGAGTTGCATCAATGGCATATATTAAAGGTGCCACA
CACAGTTTGAAGGCTGCTCTTAGAGGCGCAGGGGTATATATTTGGGCATTCGGGGATACT
GTAGTGAACTGGAATGATGCACTTGATATCGCAAATACTAGGGTTAAGATATCCCTAGAG
CAACTTCAGACCCTTACACCTCTTCCTACATCTGCAAACATTACACACCGTTTAGATGAT
GGAGCCACAACACTTAAATTCACTCCAGCTAGTTCCTATGCATTTTCTAGTTATACTCAT
ATATCAAATGATCAACAATATTTAGAAATAGATCAGAGAGTAGTCGATTCTAATATTATT
TATCAACAATTAATGATAACAGGACTTGGGATTATTGAGACCTACCATAACCCACCTATA
AGGACTTCTACACAAGAAATCACTCTCCATTTGCACACTAGCTCATCTTGTTGTGTTAGA
AGTGTAGATGGTTGCCTTATATGTGAGAGCAATGGAGAGGTTCCTCAGATCACTGTTCCC
TATACTAATACATTTGTATATGATCCTGATCCACTAGCAGATTATGAGATTGCACACCTA
GATTATCTCTCCTACCAAGCTAAAATTGGAAGTACAGATTACTACTCACTCACTGATAAA
ATTGACCTATTAGCACATTTAACTGCAAAACAAATGATAAACTCAATAATTGGGTTAGAT
GAAACAGTATCAATTGTCAATGATGCGGTTATCCTATCTGACTATACTAATAACTGGATT
AGTGAATGTTCTTATACTAAGATAGATTTAGTTTTTAAATTAATGGCATGGAATTTCCTT
CTTGAGCTTGCATTCCAGATGTACTACTTAAGGATATCATCTTGGACAAATATATTTGAC
TATACTTATATGACTTTGCGCAGGATACCCGGAACTGCTCTAAATAATATTGCAGCTACT
ATTAGCCATCCAAAATTATTAAGACGTGCAATGAATCTTGATATTATCACTCCTATACAT
GCACCGTATTTAGCTTCATTAGATTATGTCAAATTAAGTATTGATGCAATTCAGTGGGGA
GTTAAACAAGTTCTTGCTGATTTATCAAATGGAATTGATCTTGAAATCTTGATTCTTTCA
GAGGATTCAATGGAAATTAGTGATAGGGCAATGAATCTCATTGCTAGAAAACTAACTCTC
CTTGCACTTGTTAAAGGTGAGAACTATACTTTTCCAAAAATTAAAGGGATGCCACCAGAA
GAAAAGTGTTTAGTCTTAACTGAATATCTAGCAATGTGTTATCAAAATACTCATCACTTA
GATCCAGATCTTCAAAAGTATTTATATAATCTAACTAATCCAAAATTGACTGCATTTCCC
AGTAACAACTTCTACTTAACTAGAAAAATCCTTAATCAAATTAGAGAATCAGACGAAGGA
CAATATATTATCACCTCATATTATGAATCCTTCGAACAATTAGAAACAGATATAATTCTT
CACTCTACTTTAACTGCTCCTTATGATAATTCAGAAAACTCTAACAAAGTTCGATTTATC
CCTTTCGACATCTTTCCACATCCAGAATCTCTCGAGAAATATCCTCTTCCAGTTGATCAT
GACTCTCAATCTGCAATTTCAACACTAATTCCAGGCCCTCCTTCTCATCATGTATTACGA
CCACTAGGAGTGTCATCCACAGCTTGGTATAAAGGGATAAGTTATTGTAGATACCTAGAA
ACACAAAAGATACAGACTGGTGATCATCTTTATTTAGCCGAAGGAAGCGGTGCTTCAATG
TCACTTCTAGAACTCTTATTTCCAGGAGATACTGTCTATTATAATAGTCTTTTTAGTAGT
GGAGAGAATCCTCCACAGAGAAACTATGCCCCTCTTCCAACTCAATTTGTACAGAGTGTT
CCATATAAATTGTGGCAAGCTGATCTTGCTGATGATAGCAATTTGATAAAAGATTTTGTC
CCATTATGGAATGGAAACGGTGCAGTTACAGACTTATCAACAAAGGATGCAGTTGCATTC
ATAATACATAAAGTAGGAGCAGAGAAAGCATCCCTTGTCCATATAGATCTCGAATCAACT
GCTAATATAAATCAGCAAACTCTGTCCAGATCCCAGATTCATTCATTAATTATAGCAACT
ACTGTTCTTAAGAGGGGTGGGATATTAATTTATAAAACATCATGGCTTCCGTTTTCTAGG
TTTAGTCAACTAGCAGGTCTACTTTGGTGCTTCTTTGACCGGATCCATCTAATACGTAGT
AGCTATTCTGATCCTCACAGTCATGAGGTTTATCTTGTATGTAGACTTGCCGCAGATTTT
AGAACTATCGGTTTCAGTGCAGCTCTAGTAACTGCTACTACTCTTCACAATGACGGATTC
ACAACAATACATCCTGATGTTGTTTGTAGTTATTGGCAACACCATCTTGAAAATGTTGGG
AGAGTCGGAAAAGTAATTGATGAGATACTTGATGGTTTAGCCACCAACTTCTTCGCAGGA
GATAATGGGCTTATTCTAAGATGTGGAGGAACTCCAAGCTCCAGAAAATGGTTAGAGATT
GACCAGTTAGCATCATTTGATTTGGTTCAAGATGCTCTGGTTACACTTATCACTATACAC
CTAAAGGAAATTATAGAAGTGCAGTCATCACATACAGAGGATTATACATCTCTCCTCTTC
ACACCTTATAATATTGGTGCAGCAGGGAAAGTCAGAACTATCATCAAATTAATTCTAGAA
CGATCTTTAATGTATACAGTCCGAAATTGGTTAGTTTTACCCAGTTCCATCCGGGATTCT
GTACGACAAGATTTAGAATTAGGGTCATTTAGATTAATGTCTATTTTAAGTGAACAGACA
TTTCTTAAAAAGACACCCACAAAAAAATACTTACTTGATCAGCTTACAAGGACATATATA
TCAACCTTCTTTAACTCTCACTCAGTCCTTCCCCTCCACCGTCCATATCAAAAACAAATA
TGGAAAGCCTTAGGTAGTGTAATATATTGTTCGGAGACAGTTGATATACCTCTAATTAAA
GACATTCAGATAGAAGATATTAATGATTTTGAAGATATCGAGAGGGGTATCGATGGCGAA
GAATTATGA
Target 4 GenBank Gene ID
Target 4 GeneCard ID Not Available
Target 4 GenAtlas ID Not Available
Target 4 HGNC ID Not Available
Target 4 Chromosome Location 6
Target 4 Locus 6p21.3
Target 4 SNPs SNPJam Report Link Image
Target 4 General References
  1. Kawano M, Okamoto K, Bando H, Kondo K, Tsurudome M, Komada H, Nishio M, Ito Y: Characterizations of the human parainfluenza type 2 virus gene encoding the L protein and the intergenic sequences. Nucleic Acids Res. 1991 May 25;19(10):2739-46. [PubMed Link Image]
Target 4 Drug References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed Link Image]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed Link Image]
Drug Target 5 [top]
Target 5 ID 838
Target 5 Name Inosine-5'-monophosphate dehydrogenase 1
Target 5 Synonyms
  1. EC 1.1.1.205
  2. IMP dehydrogenase 1
  3. IMPD 1
  4. IMPDH-I
Target 5 Gene Name IMPDH1
Target 5 Protein Sequence >Inosine-5'-monophosphate dehydrogenase 1 
MADYLISGGTGYVPEDGLTAQQLFASADGLTYNDFLILPGFIDFIADEVDLTSALTRKIT
LKTPLISSPMDTVTEADMAIAMALMGGIGFIHHNCTPEFQANEVRKVKKFEQGFITDPVV
LSPSHTVGDVLEAKMRHGFSGIPITETGTMGSKLVGIVTSRDIDFLAEKDHTTLLSEVMT
PRIELVVAPAGVTLKEANEILQRSKKGKLPIVNDCDELVAIIARTDLKKNRDYPLASKDS
QKQLLCGAAVGTREDDKYRLDLLTQAGVDVIVLDSSQGNSVYQIAMVHYIKQKYPHLQVI
GGNVVTAAQAKNLIDAGVDGLRVGMGCGSICITQEVMACGRPQGTAVYKVAEYARRFGVP
IIADGGIQTVGHVVKALALGASTVMMGSLLAATTEAPGEYFFSDGVRLKKYRGMGSLDAM
EKSSSSQKRYFSEGDKVKIAQGVSGSIQDKGSIQKFVPYLIAGIQHGCQDIGARSLSVLR
SMMYSGELKFEKRTMSAQIEGGVHGLHSYEKRLY
Target 5 Number of Residues 522
Target 5 Molecular Weight 55407
Target 5 Theoretical pI 6.90
Target 5 GO Classification
Function
catalytic activity
oxidoreductase activity
oxidoreductase activity, acting on CH-OH group of donors
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
IMP dehydrogenase activity
Process
physiological process
metabolism
cellular metabolism
nucleobase, nucleoside, nucleotide and nucleic acid metabolism
nucleotide metabolism
purine nucleotide metabolism
purine nucleotide biosynthesis
purine nucleoside monophosphate biosynthesis
purine ribonucleoside monophosphate biosynthesis
GMP biosynthesis
Component
Not Available
Target 5 General Function Nucleotide transport and metabolism
Target 5 Specific Function Rate limiting enzyme in the de novo synthesis of guanine nucleotides and therefore is involved in the regulation of cell growth. It may also have a role in the development of malignancy and the growth progression of some tumors
Target 5 Pathways
Name SMPDB Link KEGG Link
Purine metabolism SMP00050 Link Image map00230 Link Image
Target 5 Reactions
  • inosine 5'-phosphate + NAD+ + H2O = xanthosine 5'-phosphate + NADH + H+
Target 5 Pfam Domain Function
Target 5 Signals
  • None
Target 5 Transmembrane Regions
  • None
Target 5 Essentiality Non-Essential
Target 5 GenBank ID Protein 307067 Link Image
Target 5 UniProtKB/Swiss-Prot ID P20839 Link Image
Target 5 UniProtKB/Swiss-Prot Entry Name IMDH1_HUMAN Link Image
Target 5 PDB ID 1JCN Link Image
Target 5 PDB File Show
Target 5 3D Structure
Target 5 Cellular Location Not Available
Target 5 Gene Sequence >1545 bp 
ATGGCGGACTACCTGATCAGCGGCGGCACCGGCTACGTGCCCGAGGATGGGCTCACCGCG
CAGCAGCTCTTCGCCAGCGCCGACGACCTCACCTACAACGACTTCCTGATTCTCCCAGGA
TTCATAGACTTCATAGCTGATGAGGTGGACCTGACCTCAGCCCTGACCCGGAAGATCACG
CTGAAGACGCCACTCATCTCCTCCCCCATGGACACTGTGACAGAGGCTGACATGGCCATT
GCCATGGCTCTGATGGGAGGTATTGGGTTCATTCACCACAACTGCACCCCAGAGTTCCAG
GCCAATGAAGTACGCAAGGTCAAGAACTTTGAACAGGGCTTCATCACGGACCCTGTGGTG
CTGAGCCCCTCGCACACTGTGGGCGATGTGCTGGAGGCCAAGATGCGGCATGGCTTCTCT
GGCATCCCCATCACTGAGACGGGCACCATGGGCAGCAAGCTGGTGGGCATCGTCACCTCC
CGAGACATCGACTTTCTTGCTGAGAAGGACCACACCACCCTCCTCAGTGAGGTGATGACG
CCAAGGATTGAACTGGTGGTGGCTCCAGCAGGTGTGACGTTGAAAGAGGCAAATGAGATC
CTGCAGCGTAGCAAGAAAGGGAAGCTGCCTATCGTCAATGATTGCGATGAGCTGGTGGCC
ATCATCGCCCGCACCGACCTGAAGAAGAATCGAGACTACCCTCTGGCCTCCAAGGATTCC
CAGAAGCAGCTGCTCTGTGGGGCAGCTGTGGGCACCCGTGAGGATGACAAATACCGTCTG
GACCTGCTGACCCAGGCGGGGGTCGACGTCATAGTCTTCCACTCGTCCCAAGGGAATTCG
GTGTATCAGATCGCCATGGTGCATTACATCAAACAGAAGTACCCCCACCTCCAGGTGATT
GGGGGGAACGTGGTGACAGCAGCCCAGGCCAAGAACCTGATTGATGCTGGTGTGGACGGG
CTGCGCGTGGGCATGGGCTGCGGCTCCATCTGCATCACCCAGGAAGTGATGGCCTGTGGT
CGGCCCCAGGGCACTGCTGTGTACAAGGTGGCTGAGTATGCCCGGCGCTTTGGTGTGCCC
ATCATAGCCGATGGCGGCATCCAGACCGTGGGACACGTGGTCAAGGCCCTGGCCCTTGGA
GCCTCCACAGTGATGATGGGCTCCCTGCTGGCCGCCACTACGGAGGCCCCTGGCGAGTAC
TTCTTCTCAGACGGGGTGCGGCTCAAGAAGTACCGGGGCATGGGCTCACTGGATCCCATG
GAGAAGAGCAGCAGCAGCCAGAAACGATACTTCAGCGAGGGGGATAAAGTGAAGATCGCA
CAGGGTGTCTCGGGCTCCATCCAGGACAAAGGATCCATTCAGAAGTTCGTGCCCTACCTC
ATAGCAGGCATCCAACACGGCTGCCAGGATATCGGGGCCCGCAGCCTGTCTGTCCTTCGG
TCCATGATGTACTCAGGAGAGCTCAAGTTTGAGAAGCGGACCATGTCGCCCCAGATTGAG
GGTGGTGTCCATGGCCTGCACTCTTACGAAAAGCGGCTGTACTGA
Target 5 GenBank Gene ID
Target 5 GeneCard ID IMPDH1 Link Image
Target 5 GenAtlas ID IMPDH1 Link Image
Target 5 HGNC ID HGNC:6052 Link Image
Target 5 Chromosome Location 7
Target 5 Locus 7q31.3-q32
Target 5 SNPs SNPJam Report Link Image
Target 5 General References
  1. Kennan A, Aherne A, Palfi A, Humphries M, McKee A, Stitt A, Simpson DA, Demtroder K, Orntoft T, Ayuso C, Kenna PF, Farrar GJ, Humphries P: Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(-/-) mice. Hum Mol Genet. 2002 Mar 1;11(5):547-57. [PubMed Link Image]
  2. Bowne SJ, Sullivan LS, Blanton SH, Cepko CL, Blackshaw S, Birch DG, Hughbanks-Wheaton D, Heckenlively JR, Daiger SP: Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum Mol Genet. 2002 Mar 1;11(5):559-68. [PubMed Link Image]
  3. Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K: Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem. 1990 Mar 25;265(9):5292-5. [PubMed Link Image]
  4. Hager PW, Collart FR, Huberman E, Mitchell BS: Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol. 1995 May 11;49(9):1323-9. [PubMed Link Image]
Target 5 Drug References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed Link Image]
Drug Target 6 [top]
Target 6 ID 874
Target 6 Name DNA
Target 6 Synonyms
  1. Deoxyribonucleic acid
Target 6 Gene Name Not Available
Target 6 Protein Sequence Not Available
Target 6 Number of Residues 0
Target 6 Molecular Weight 7656 (double strand)
Target 6 Theoretical pI Not Available
Target 6 GO Classification
Function
information storage
information transfer
Process
DNA replication and chromosomal cycle
DNA replication
DNA-dependent DNA replication
DNA replication, synthesis of RNA primer
transcription
transcription, DNA dependent
Component
cell
intracellular
nucleus
mitochondria
Target 6 General Function Biological information storage and information transfer
Target 6 Specific Function DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.
Target 6 Pathways
Name SMPDB Link KEGG Link
DNA polymerase map03030 Link Image
RNA polymerase map03020 Link Image
Target 6 Reactions
  • DNA + DNA polymerase + nNTP = 2 DNA + nNDP; DNA + RNA polymerase + NTP = mRNA + nNDP
Target 6 Pfam Domain Function Not Available
Target 6 Signals
  • None
Target 6 Transmembrane Regions
  • None
Target 6 Essentiality Essential
Target 6 GenBank ID Protein Not Available
Target 6 UniProtKB/Swiss-Prot ID Not Available
Target 6 UniProtKB/Swiss-Prot Entry Name Not Available
Target 6 PDB ID 1BNA Link Image
Target 6 PDB File Show
Target 6 3D Structure
Target 6 Cellular Location
  • Nucleus and mitochondria
Target 6 Gene Sequence >Example: Dickerson dodecamer 
CGCGAATTCGCG
Target 6 GenBank Gene ID
Target 6 GeneCard ID Not Available
Target 6 GenAtlas ID Not Available
Target 6 HGNC ID Not Available
Target 6 Chromosome Location Not Available
Target 6 Locus All loci
Target 6 SNPs Not Available
Target 6 General References
  1. Nadeau D, Marchand C: Change in the kinetics of sulphacetamide tissue distribution in Walker tumor-bearing rats. Drug Metab Dispos. 1975 Nov-Dec;3(6):565-76. [PubMed Link Image]
Target 6 Drug References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed Link Image]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed Link Image]
  3. Ren FY, Jin H, Piao XX, Piao FS: Ribavirin and IFN-alpha combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B. World J Gastroenterol. 2007 Nov 7;13(41):5440-5. [PubMed Link Image]

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.